A structural and functional acromegaly classification

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 1, 2015, Pages 122-131

  Cuevas Ramos, Daniel ^a   Carmichael, John D ^a   Cooper, Odelia ^a   Bonert, Vivien S ^a   Gertych, Arkadiusz ^b   Mamelak, Adam N ^b   Melmed, Shlomo ^a  

^a Pituitary Center   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; KI 67 ANTIGEN; OCTREOTIDE; PEGVISOMANT; PROTEIN P16; PROTEIN P21; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2;

ACCURACY; ACROMEGALY; ADENOMA; ADULT; AGE DISTRIBUTION; ARTICLE; CAVERNOUS SINUS INVASION; CLINICAL FEATURE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEGRANULATION; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERNAL CAROTID ENCASEMENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NERVE COMPRESSION; NEUROIMAGING; NEUROSURGERY; NONAGGRESSIVE MACROADENOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PROTEIN EXPRESSION; RADIODIAGNOSIS; SPHENOID SINUS; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR VOLUME; AGED; CLASSIFICATION; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SECRETION (PROCESS);

ARACHIS HYPOGAEA;

ACROMEGALY; ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PITUITARY NEOPLASMS;

EID: 84920568267     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2468     Document Type: Article

References (36)

1. Melmed S. Medical progress: acromegaly.NEngl J Med. 2006;355: 2558-2573.
2. Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013;98:1040-1050.
3. Jane JA Jr., Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96:2732-2740.
4. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not ch ange from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf). 2010;72:203-208.
5. Melmed S, Braunstein GD, Horvath E, Ezrin C, Kovacs K. Pathophysiology of acromegaly. Endocr Rev. 1983;4:271-290.
6. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667-674.
7. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in pa tients with acromegaly. J Clin Endocrinol Metab. 2004;89: 1613-1617.
8. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive va lue of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89:2789-2796.
9. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33:610-6 17; discussion 617-618.
10. Albarel F, Castinetti F, Morange I, et al. Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clin Endocrinol (Oxf). 2013;78:263-270.
11. Mamelak AN, Carmichael J, Bonert VH, Cooper O, Melmed S. Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary. 2013; 16: 393-401.
12. Kreutzer J, VanceML,LopesMB,LawsERJr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86:4072-4077.
13. Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr. Endoscopic vs microsurgical transsphenoidal surgery for acro-megaly: outcomes in a concurrent series of patients using moder n criteria for remission. J Clin Endocrinol Metab. 2013;98:3190-3198.
14. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr. Atypical pituitary adenomas: incidence, clini cal characteristics, and implications. J Neurosurg. 2011;114:336-344.
15. Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32:247-271.
16. Kleinberg DL. Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs. Rev Endocr Metab Disord. 2005;6:29-37.
17. Ben-Shlomo A,Melmed S. Pituitary somatostatin receptor signaling Trends Endocrinol Metab. 2010 21 123-133.
18. Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Gro wth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16:490-498.
19. Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters BK, Wierman ME. Clinical implications of growth hormone-secreting tumor subtypes. Endocrine. 2012;42:18-28.
20. Horvath E, Kovacs K. Pathology of acromegaly. Neuroendocrinology. 2006;83:161-165.
21. Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O. Granulation pattern, b ut not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol. 2013;168:491-499.
22. Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schö fl C. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol. 2013;169:391-400.
23. Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly . Clin Endocrinol (Oxf). 2012;76:96-102.
24. Chesnokova V, Zonis S, Kovacs K, et al. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA. 2008;105:17498-17503.
25. Chesnokova V, Zonis S, Zhou C, et al. Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One. 2011;6: e17924.
26. Quereda V, Martinalbo J, D ubus P, Carnero A, Malumbres M. Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression. Oncogene. 2007;26:7665-7674.
27. Woloschak M, Yu A, Xiao J, Post KD. Frequent loss of the P16INK4a gene product in human pituitary tumors. Cancer Res. 1996;56:2493-2496.
28. Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab. 2000;85:168-174.
29. Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assess ment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94:523-527.
30. Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243-248.
31. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189-3202.
32. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7:257-266.
33. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019-1031.
34. Holdaway IM, Bolland MJ, Gamble GD. A meta-Analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.
35. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61-67.
36. Jaffrain-Rea ML, Di Stefano D, Minniti G, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9:103-113.